Dataset ID: 10
Dataset Details
Study Design
| Study Design Background |
To investigate if ultrasound-mediated blood-brain barrier opening or drug formulation in polymetic nanoparticles can increase the acuumulation of cabazitazel in the brain or theapeutic effect for glioblastoma.
|
|---|---|
| Study Description |
FUS for BBB opening
|
| Study Type |
Preclinical
|
| Study Subtype |
In vivo
|
Publication
| Paper Linked | |
|---|---|
| Paper Title |
Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model
|
| Paper Authors |
Sulheim, Einar, Mørch, Yrr, Snipstad, Sofie, Borgos, Sven Even, Miletic, Hrvoje, Bjerkvig, Rolf, de Lange Davies, Catharina, Åslund, Andreas K.O.
|
| Affiliation |
Department of Physics, Norwegian University of Science and Technology (NTNU), Trondheim, Norway ; Department of Biotechnology and Nanomedicine, SINTEF AS, Trondheim Norway ; Department of Biotechnology and Nanomedicine, SINTEF AS, Trondheim Norway ; Cancer Clinic, St.Olav’s University Hospital, Trondheim Norway ; Department of Pathology, Haukeland University Hospital, Bergen, Norway ; Department of Biomedicine, University of Bergen, Norway ; Department of Oncology, Luxembourg Institute of Health, Luxembourg ; Stroke Unit, Department of internal medicine, St. Olav's University Hospital, Trondheim, Norway
|
| Paper Journal |
Nanotheranostics
|
| Paper Year |
2019
|
| Paper DOI | |
| Open Access |
Yes
|
Study Component
| Multi Modality Images |
No
|
|---|---|
| Imaging Modality |
MRI
|
| Imaging Sub Modality |
T2W, DCE
|
| Radiation |
No
|
| Imaging Coverage |
Brain
|
| Imaging Target |
Anatomy, vascular permeability
|
Dataset Information
| Institution |
NTNU
|
|---|---|
| PI |
Andreas K.O. Åslund
|
| Country Of Institution |
Norway
|
| Imaging Facility |
MR Core
|
| Euro Bio Imaging Node |
NORMOLIM
|
| Country Of Imaging Facility |
Norway
|
In Vivo Experimental Parameters
| Number Of Groups |
4
|
|---|---|
| Types Of Groups |
Cab-NPMB and FUS; cab, empty NPMB and FUS; cab; saline control
|
| Overall Sample Size |
15
|
| Disease Model |
Cancer
|
| Organ Or Tissue |
Brain
|
| Sample Size For Each Group |
3 for cab-NPMB and FUS; 4 for cab, empty NPMB and FUS; 4 for cab; 4 for saline control
|
| Randomization |
Yes mice were randomly divided into four groups
|
| Blinding |
No
|
| Outcome Measures |
Tumor growth, cab accumulation using mass spectrometry, signal ratio of treated non-treated hemisphere
|
| Statistical Methods |
Not stated
|
| Species |
Mice
|
| Strain |
NOD SCID, Balb c nudes
|
| Immune Status |
Immunedeficient
|
| Sex |
Female
|
| Age |
Older than 8 weeks
|
| Age At Start Experiment |
Older than 8 weeks
|
| Age At Scanning Experiment S |
Older than 11 weeks, weekly scanning
|
| Weight |
About 20 g
|
| Weight At Start Experiment |
About 20 g
|
| Weight At End Experiment |
About 20 g
|
| Source Of Animals |
Janvier Labs
|
Experimental Procedures
| Pharmacological Drug |
Jevtana® (Cabazitaxel), and poly(2-ethyl butylcyanoacrylate) (PEBCA) NPs (cab-NPs, diameter 153 nm) and NP stabilized microbubbles (NPMBs, diamter > 1000 nm) (experimental)
|
|---|---|
| Company |
Sanofi-Aventis
|
| Drug Dose |
10
|
| Volume |
0,05
|
| Site Or Route Of Administration |
Intravenous
|
| Frequency Of Administration |
Two times, with a week apart
|
| Vehicle Or Carrier Solution Formulation |
Saline
|
| Blood Sampling |
No
|
| Surgical Procedures Including Sham Surgery |
Yes
|
| Description Of The Surgical Procedure |
Intracranial inoculation of glioma cells. The skin was sterilized by ethanol and a 1 cm sagittal incision was made to expose the bregma. A hole was drilled at the coordinates A +1, L -2 and V -3.5 mm in relation to bregma. 5 ?l cell suspension (200 000 cells) was aspirated into a 25 ?l Hamilton syringe (Model 1702 N). The syringe was mounted onto a stereotactic frame and inserted into the brain slowly for 4 mm and then retracted 0.5 mm, before the injection. The injection was performed over 3 minutes and 2 minutes later the syringe was slowly retracted.
|
| Target Organ Tissue |
Brain
|
| Pathogen Infection Intervention And Control |
No
|
| Analgesic Plan To Relieve Pain Suffering And Distress |
Yes
|
| Analgesic Name |
Marcain
|
| Route |
Subcutaneous injection
|
| Analgesic Dose |
1:5, 0.04 ml 20g
|
| Anesthesia Type |
Gas
|
| Duration |
~30 minutes
|
| Anesthesia Drugs |
Isoflurane
|
| Anesthesia Dose |
~2% in 78% medical air 20% O2
|
| Euthanasia |
Yes
|
| Method |
Cervical dislocation
|
| Histology |
Yes
|
| Tissues Collected Post Euthanasia |
Brain
|
| Timing Of Collection |
After the last scanning
|
| Histological Procedure |
Formalin fixed
|
| Name Of Reagent S |
Anti-P-gp antibody
|
| Catalogue Number |
EPR10364-57, Abcam
|
| Frequency Of Imaging |
Weekly
|
| Timing Of Imaging |
Three weeks after inoculation
|
| Overall Scan Length |
~ 6 minutes (for tumour development evaluation)
|
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule |
Yes
|
| Contrast Agent Commercial Drug |
Omniscan
|
| Contrast Agent Chemical Drug |
Gadolinium
|
| Route Of Administration |
Intravenous
|
| Cell Line |
P3, patient derived
|
| Modified Cell Line |
No
|
| Cell Injection Route |
Intracranial
|
| Number Of Cells |
200 000 cells
|
| Housing Room |
SPF
|
| Dietary Intervention |
No
|
| Respiration Rate |
Only during scanning
|
| Body Tempurature Etc |
Only during scanning
|
| Food Intake Measured |
No
|
Image Acquisition
| Instrument Vendor |
Bruker
|
|---|---|
| Instrument Type |
Bio Spec 70 20
|
| Instrument Specifics |
7T
|
| Raw Data |
Yes
|
| QA/QC |
Yes, annual QC
|
Image Data
| Image Type |
Primary image
|
|---|---|
| Format Compression |
DICOM, raw
|
| Dimensions |
2D
|
| Overall Number Of Images |
T2-RARE for anatomy, FLASH to evaluate BBB-opening,3x FLASH acquired
|
| Field Of View |
20mm x 20mm
|
| Dimension Extents |
200 x 200 x 1mm
|
| Size Description |
20mm x 20mm x 9mm
|
| PI xel Voxel Size Description |
100um x 100 um x 1mm
|
| Ai Enhanced Algorithm |
No
|
Analyzed Data
| Analysis Result Type |
Numerical
|
|---|---|
| Data Used For Analysis |
Volume measurements, ratio of signal from treated and untreated hemispheres
|
| Analysis Method And Details |
HOROS
|
| Status |
Complete
|
| Updated Year |
2023
|